Pancreatic cancer (PC) is the worst prognosis cancer globally, with just 13% of patients who are diagnosed with PC surviving for 5 years or more after initial diagnosis. In Ireland, there are approximately 900 cases of PC per year, and 820 PC-related deaths. Early detection of PC is the primary concern of most PC research, as it has the potential to make a substantial difference to the treatment and survival of patients.

Pancreatic cancer is fueled by connections to the nervous system. This is reported by scientists from the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) in Nature.

In a surprising discovery, scientists have found that the heart possesses “sweet taste” receptors, similar to those on our tongues, and that stimulating these receptors with sweet substances can modulate the heartbeat. This research opens new avenues for understanding heart function and potentially for developing novel treatments for heart failure.

A debilitating condition affecting 1 in 4 women is desperately crying out for a solution, and the next generation of treatments to repair the damage of pelvic organ prolapse (POP) has just come a big step closer.

They combined a blend of slimy and sticky proteins to produce a fast-acting, bacteria-blocking, waterproof adhesive for use in biomedical applications.

Boston Scientific (NYSE: BSX)+
announced today that it received CE mark for its navigation-enabled Farawave Nav ablation catheter and Faraview software.